Trials / Completed
CompletedNCT00035035
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GEMZAR | |
| DRUG | ALIMTA |
Timeline
- First posted
- 2002-05-03
- Last updated
- 2006-07-19
Locations
114 sites across 18 countries: United States, Argentina, Australia, Austria, Belgium, Colombia, France, Germany, Greece, Italy, Netherlands, Peru, Portugal, Spain, Sweden, Taiwan, United Kingdom, Venezuela
Source: ClinicalTrials.gov record NCT00035035. Inclusion in this directory is not an endorsement.